Cotreatment with Vorinostat Enhances Activity of MK-0457 (VX-680) Against Acute and Chronic Myelogenous Leukemia Cells

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2008 Oct 3

PMID 18829489

Citations 35

Authors

Warren Fiskus

Yongchao Wang

Rajeshree Joshi

Rekha Rao

Yonghua Yang

Jianguang Chen

Ravindra Kolhe

Ramesh Balusu

Kelly Eaton

Pearl Lee

Celalettin Ustun

Anand Jillella

Carolyn A Buser

Stephen Peiper

Kapil Bhalla

Affiliations

Soon will be listed here.

Abstract

Purpose: We determined the effects of vorinostat (suberoylanalide hydroxamic acid) and/or MK-0457 (VX-680), an Aurora kinase inhibitor on the cultured human (HL-60, OCI-AML3, and K562) and primary acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML), as well as on the murine pro-B BaF3 cells with ectopic expression of the unmutated and mutant forms of Bcr-Abl.

Experimental Design: Following exposure to MK-0457 and/or vorinostat, apoptosis, loss of viability, as well as activity and levels of Aurora kinase and Bcr-Abl proteins were determined.

Results: Treatment with MK-0457 decreased the phosphorylation of Aurora kinase substrates including serine (S)10 on histone H3 and survivin, and led to aberrant mitosis, DNA endoreduplication as well as apoptosis of the cultured human acute leukemia HL-60, OCI-AML3, and K562 cells. Combined treatment with vorinostat and MK-0457 resulted in greater attenuation of Aurora and Bcr-Abl (in K562) kinase activity and levels as well as synergistically induced apoptosis of OCI-AML3, HL-60, and K562 cells. MK-0457 plus vorinostat also induced synergistic apoptosis of BaF3 cells with ectopic overexpression of wild-type or mutant Bcr-Abl. Finally, cotreatment with MK-0457 and vorinostat induced more loss of viability of primary AML and imatinib-refractory CML than treatment with either agent alone, but exhibited minimal toxicity to normal CD34+ progenitor cells.

Conclusions: Combined in vitro treatment with MK-0457 and vorinostat is highly active against cultured and primary leukemia cells. These findings merit in vivo testing of the combination against human AML and CML cells, especially against imatinib mesylate-resistant Bcr-AblT315I-expressing CML Cells.

Citing Articles

Recent Updates on Oncogenic Signaling of Aurora Kinases in Chemosensitive, Chemoresistant Cancers: Novel Medicinal Chemistry Approaches for Targeting Aurora Kinases.

Kumari P, Beeraka N, Tengli A, Bannimath G, Baath R, Patil M Curr Med Chem. 2023; 31(23):3502-3528.

PMID: 37138483 DOI: 10.2174/0929867330666230503124408.

A novel dual HDAC and HSP90 inhibitor, MPT0G449, downregulates oncogenic pathways in human acute leukemia in vitro and in vivo.

Wu Y, Chao M, Tu H, Chen L, Hsu K, Liou J Oncogenesis. 2021; 10(5):39.

PMID: 33986242 PMC: 8119482. DOI: 10.1038/s41389-021-00331-0.

Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy.

Du R, Huang C, Liu K, Li X, Dong Z Mol Cancer. 2021; 20(1):15.

PMID: 33451333 PMC: 7809767. DOI: 10.1186/s12943-020-01305-3.

HDAC Inhibitors in Acute Myeloid Leukemia.

Jose-Eneriz E, Gimenez-Camino N, Agirre X, Prosper F Cancers (Basel). 2019; 11(11).

PMID: 31739588 PMC: 6896008. DOI: 10.3390/cancers11111794.

An Aurora kinase inhibitor, AMG900, inhibits glioblastoma cell proliferation by disrupting mitotic progression.

Ryu J, Pyo J, Lee C, Kim J Cancer Med. 2018; 7(11):5589-5603.

PMID: 30221846 PMC: 6246935. DOI: 10.1002/cam4.1771.

References

Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M . Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell. 2003; 114(5):585-98. DOI: 10.1016/s0092-8674(03)00642-1. View

Harrington E, Bebbington D, Moore J, Rasmussen R, Ajose-Adeogun A, Nakayama T . VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med. 2004; 10(3):262-7. DOI: 10.1038/nm1003. View

Guo F, Sigua C, Tao J, Bali P, George P, Li Y . Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res. 2004; 64(7):2580-9. DOI: 10.1158/0008-5472.can-03-2629. View

Bali P, George P, Cohen P, Tao J, Guo F, Sigua C . Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin Cancer Res. 2004; 10(15):4991-7. DOI: 10.1158/1078-0432.CCR-04-0210. View

Chou T, Talalay P . Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27-55. DOI: 10.1016/0065-2571(84)90007-4. View

Fukushige S, Waldman F, Kimura M, Abe T, Furukawa T, Sunamura M . Frequent gain of copy number on the long arm of chromosome 20 in human pancreatic adenocarcinoma. Genes Chromosomes Cancer. 1997; 19(3):161-9. DOI: 10.1002/(sici)1098-2264(199707)19:3<161::aid-gcc5>3.0.co;2-w. View

Bischoff J, Anderson L, Zhu Y, Mossie K, Ng L, Souza B . A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 1998; 17(11):3052-65. PMC: 1170645. DOI: 10.1093/emboj/17.11.3052. View

Weisberg E, Manley P, Cowan-Jacob S, Hochhaus A, Griffin J . Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer. 2007; 7(5):345-56. DOI: 10.1038/nrc2126. View

Jiang X, Saw K, Eaves A, Eaves C . Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst. 2007; 99(9):680-93. DOI: 10.1093/jnci/djk150. View

10.

Cheetham G, Charlton P, Golec J, Pollard J . Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett. 2007; 251(2):323-9. DOI: 10.1016/j.canlet.2006.12.004. View

11.

Peng C, Brain J, Hu Y, Goodrich A, Kong L, Grayzel D . Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood. 2007; 110(2):678-85. PMC: 1924476. DOI: 10.1182/blood-2006-10-054098. View

12.

Schmit T, Ahmad N . Regulation of mitosis via mitotic kinases: new opportunities for cancer management. Mol Cancer Ther. 2007; 6(7):1920-31. DOI: 10.1158/1535-7163.MCT-06-0781. View

13.

Glozak M, Seto E . Histone deacetylases and cancer. Oncogene. 2007; 26(37):5420-32. DOI: 10.1038/sj.onc.1210610. View

14.

Yang J, Ikezoe T, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y . AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood. 2007; 110(6):2034-40. DOI: 10.1182/blood-2007-02-073700. View

15.

Dokmanovic M, Clarke C, Marks P . Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res. 2007; 5(10):981-9. DOI: 10.1158/1541-7786.MCR-07-0324. View

16.

Nishida N, Nagasaka T, Kashiwagi K, Boland C, Goel A . High copy amplification of the Aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers. Cancer Biol Ther. 2007; 6(4):525-33. DOI: 10.4161/cbt.6.4.3817. View

17.

Park J, Jong H, Kim S, Jung Y, Lee K, Lee J . Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase. J Mol Med (Berl). 2007; 86(1):117-28. DOI: 10.1007/s00109-007-0260-8. View

18.

Lange B, Rebollo E, Herold A, Gonzalez C . Cdc37 is essential for chromosome segregation and cytokinesis in higher eukaryotes. EMBO J. 2002; 21(20):5364-74. PMC: 129064. DOI: 10.1093/emboj/cdf531. View

19.

Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J . Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 2003; 63(16):5126-35. View

20.

Zhou H, Kuang J, Zhong L, Kuo W, Gray J, Sahin A . Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet. 1998; 20(2):189-93. DOI: 10.1038/2496. View